Proactive Investor – Interview with CEO Christopher Moreau regarding the approval from the Data and Safety Monitoring Board to continue the study

Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news that the company has heard from the external Data and Safety Monitoring Board which has once again unanimously approved the continuation of the Company’s multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19.

Moreau talks about moving forward his thoughts about Ifenprodil compared to others.

Share via
Copy link
Powered by Social Snap